Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide treatment in multiple myeloma.

Kathrin Strasser1, Heinz Ludwig

  • 11st Department of Medicine and Oncology, Wilhelminenspital, Vienna, Austria.

Blood Reviews
|September 28, 2002
PubMed
Summary

Thalidomide shows promise in multiple myeloma treatment, with ongoing research into optimal dosing and combinations. New analogues, immunomodulatory drugs (IMiDs), are being developed for potentially improved efficacy and reduced toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Temporal trends in progression risk in smoldering myeloma: a systematic review.

EClinicalMedicine·2026
Same author

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Annals of hematology·2026
Same author

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

HemaSphere·2025
Same author

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years.

Cancers·2025
Same author

Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice.

Annals of hematology·2025

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Thalidomide was initially investigated for refractory multiple myeloma in the 1990s.
  • Promising early results led to its use in earlier stages of multiple myeloma.
  • Numerous Phase II studies have explored various thalidomide doses and schedules.

Purpose of the Study:

  • To review clinical data on thalidomide's efficacy and toxicity in multiple myeloma.
  • To discuss the proposed mechanisms of action for thalidomide.
  • To explore future research directions and clinical development of thalidomide analogues (IMiDs).

Main Methods:

  • Review of published Phase II clinical trial data.
  • Analysis of toxicity profiles from various treatment settings.
  • Examination of preclinical data for thalidomide analogues (IMiDs).

Main Results:

  • Thalidomide has demonstrated efficacy in multiple myeloma, leading to combination therapies.
  • Data on thalidomide's toxicity profile has been collected across multiple trials.
  • Ongoing trials are evaluating thalidomide in newly diagnosed patients and exploring IMiDs.

Conclusions:

  • Optimal thalidomide dosage and combination schedules require further definition.
  • The precise mechanism of action of thalidomide remains to be fully elucidated.
  • Thalidomide analogues (IMiDs) show potential for improved therapeutic outcomes in multiple myeloma.

Related Experiment Videos